Inmunoterapia para las infecciones recurrentes del tracto urinario: efectos de un extracto de escherichia coli: [revisión] / Immunotherapy for recurrent urinary tract infections: effects of an escherichia coli extract: [review]

La carga de las infecciones del tracto urinario (ITU) es alta en el mundo entero. Debido a que los tratamientos causales de estas infecciones frecuentemente recurrentes tienen límites sustanciales, las medidas preventivas merecen la prioridad. Entre ellas, la inmunoestimulación con extractos bacterianos ha demostrado que previene las ITUs y que es muy segura. Esta revisión enfoca el inmunoestimulante OM-89, un extracto liofilizado de Escherichia coli producido mediante biotecnología, formulado para la administración por vía oral a partir de este germen frecuentemente responsable de las ITU, y cubrirá sus efectos farmacológicos y clínicos con respecto a eficacia y seguridad. Se pondrá énfasis especial en los estudios clínicos realizados en niños, adultos y pacientes especiales así como en un estudio que evaluó el efecto de OM-89 sobre la calidad de vida de los pacientes.

Efficacy and Safety of Uro-Vaxom Treatment for Patients with Recurrent Cystitis: An Open Multicenter Study / 대한비뇨기과학회지

PURPOSE: We wanted to investigate the efficacy and safety of the immunotherapeutic Uro-Vaxom for treating uncomplicated recurrent cystitis in female patients only. MATERIALS AND METHODS: Adult female patients were enrolled in this multicenter, open-label study if they had acute cystitis at the enrollment visit and positive results on urine culture (> or =10(3)CFU/ml). The patients were treated for 3 months with one capsule daily of Uro-Vaxom after antibiotic therapy, and they were observed for another 3 months. The primary efficacy criteria were the cystitis recurrence rates over 6 months, the distribution of cystitis and the proportion of patients with cystitis. RESULTS: A total of 50 patients were evaluated. During the 6-month trial, the number of cystitis recurrences was significantly reduced in comparison with the 6-month pretrial period (on the average 0.64 as compared to 3.0 recurrences, respectively p<0.001). The incidences of frequency, urgency and dysuria remained low until the end of the trial. Uro-Vaxom was well tolerated: side-effects were mentioned by 8% of the 50 patients, and there was no case leading to treatment withdrawal. CONCLUSIONS: Uro-Vaxom significantly reduced the incidence of cystitis during the 6 months of this study, including the 3 months of treatment. These results demonstrate that Uro-Vaxom is a valuable agent for prophylaxis of recurrent cystitis.

The Recurrence of Chronic Pelvic Pain Syndrome and the Role of Uro-Vaxom(R) / 대한비뇨기과학회지

PURPOSE: Chronic pelvic pain syndrome (CPPS) is the most common urogenital disease in middle aged men, and it shows various symptoms and a high recurrent rate. Uro-Vaxom(R) is effective for the treatment of urinary tract infection via the activation of the urothelial immune system. The main objectives of this study were to investigate the recurrence of CPPS and to find out if Uro-Vaxom(R) is helpful to suppress the recurrence of this condition. MATERIALS AND METHODS: After completing treatment for CPPS (NIH-IIIa 45, NIH-IIIb 85), 130 patients were given a 12 week course of Uro-Vaxom(R) 60mg once a day before breakfast. Sixty patients were also included in the study as a control group after they completed the treatment for CPPS (NIH-IIIa 22, NIH-IIIb 38). All of patients were reevaluated 12 weeks and 24 weeks later with the NIH-CPSI criteria and the EPS findings. RESULTS: The overall recurrent rate for NIH-IIIa disease was 22.7%, and it was 26.3% for the patients with NIH-IIIb disease in the control group, and it was 6.7% for the patients with NIH-IIIa disease and 7.1% for the patients with NIH-IIIb disease in the Uro-Vaxom(R) group (p<0.05). The classification of the recurrent CPPS was 46.7% NIH-IIIa and 53.3% NIH- IIIb in the control group, and 11.1% NIH-IIIa and 88.9% NIH-IIIb in the Uro-Vaxom(R) group. The possible predisposing factors related to the recurrence of CPPS were excessive alcoholic drinking (29.2%), overwork (25.0%) and stress (16.7%). In the non-recurrent patients, there was no change of the NIH-Chronic Prostatitis Symptom Index and the EPS findings for all patients during the follow-up period. CONCLUSIONS: There was about a 30% recurrence rate of CPPS within 6 months after treatment, and Uro-Vaxom(R) may play a significant role to suppress the recurrence of CPPS.

The Application of Uro-vaxom(R), Urinary Tract Immunostimulator in the Treatment of Chronic Pelvic Pain Syndrome / 대한비뇨기과학회지

Purpose: There are a variety of techniques for treating chronic prostatitis. Regardless of the presence of infections, antibiotics were arbitrarily prescribed for 4-12 weeks, but there seemed to be ongoing debate of their effectiveness and side effects. Uro-vaxom(R) is known as an effective treatment for urinary tract infection due to its initiation the urothelial immune system activity. This study was performed to investigate for the possibility of Uro-vaxom(R) as a drug for use in non-inflammatory chronic prostatitis. Materials and Methods: 95 patients, diagnosed as chronic pelvic pain syndrome (CPPS) (National Institutes of Health (NIH)-category IIIB), were divided into three groups: group A, 35 patients were given levofloxacin 100mg TID and Uro-vaxom(R) 60mg OD for the first 4 weeks, followed by only Uro-vaxom(R) 60mg OD for the next 8 weeks; group B, 30 patients were given only Uro-vaxom(R) 60mg OD before breakfast for 12 weeks; group C, the patients were treated with levofloxacin 100mg TID for 4 weeks. All the patients were reevaluated 4 weeks and 12 weeks later. Results: The initial diagnostic stati, the NIH-Chronic Prostatitis Symptom Index (CPSI) were 25.1+/-2.7, 24.4+/-3.2 and 24.7+/-2.2 for groups A, B and C, respectively. In groups A and B, the NIH-CPSI after 12 weeks were 13.5 2.3 and 13.9+/-2.7, respectively, and showed noticeable improvements (p0.05). No patients experienced any adverse symptoms due to Uro-vaxom(R) intake. Conclusions: Uro-vaxom(R) could be appointed as an alternative method for the treatment of chronic prostatitis.